ArticleCancer letters2016
Serum miRNAs as predictive and preventive biomarker for pre-clinical hepatocellular carcinoma.
Open access · greenAbstract read
In one paragraph
Article in Cancer letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- MicroRNA-21 Expression as a Prognostic Biomarker in Oral Cancer: Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.The Cochrane database of systematic reviews · 2021Pooled it
- Study on the value and mechanism of miR-369-5p in childhood pneumonia.BMC immunology · 2026Article
- circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR-338-5p/IL-7 pathway.Journal of cellular and molecular medicine · 2024Article
- Article
- Dual mechanism of Let-7i in tumor progression.Frontiers in oncology · 2023Review
- Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma.BMC gastroenterology · 2022Article
- circMRPS35 promotes malignant progression and cisplatin resistance in hepatocellular carcinoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- The role of miR-200 family in the regulation of hallmarks of cancer.Frontiers in oncology · 2022Review
- CircFGGY Inhibits Cell Growth, Invasion and Epithelial-Mesenchymal Transition of Hepatocellular CarcinomaFrontiers in cell and developmental biology · 2022Article
- Circ-RNF13, as an oncogene, regulates malignant progression of HBV-associated hepatocellular carcinoma cells and HBV infection through ceRNA pathway of circ-RNF13/miR-424-5p/TGIF2.Bosnian journal of basic medical sciences · 2021Article
- [Expert consensus on early screening strategies for liver cancer in China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Article
- [Research progress of serum biomarkers for early screening of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Article
- Prediction of hepatocellular carcinoma risk in patients with chronic liver disease from dynamic modular networks.Journal of translational medicine · 2021Article
- MicroRNA-103a-3p Promotes Cell Proliferation and Invasion in Non-Small-Cell Lung Cancer Cells through Akt Pathway by Targeting PTEN.BioMed research international · 2021Article
- Early lung cancer diagnostic biomarker discovery by machine learning methods.Translational oncology · 2021Article
- Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma.Frontiers in oncology · 2021Review
- Research Trends in the Efficacy of Stem Cell Therapy for Hepatic Diseases Based on MicroRNA Profiling.International journal of molecular sciences · 2020Review
- Mechanisms and Functions of MiR-200 Family in Hepatocellular Carcinoma.OncoTargets and therapy · 2020Review
- Paeonol Inhibits Cell Proliferation, Migration and Invasion and Induces Apoptosis in Hepatocellular Carcinoma by Regulating miR-21-5p/KLF6 Axis.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 11 institutions in 2 countries.
Liang LiInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer, Shanghai, China.
Jianguo ChenQidong Liver Cancer Institute and Nantong University Liver Cancer Institute, QiDong 226200, Jiangsu, China.
Xin ChenInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer, Shanghai, China.
Jing TangInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer, Shanghai, China.
Huan GuoMOE Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Rd, Wuhan 430030, China.
Xiaofeng WangState Key Lab of Genetic Engineering and MOE Key Lab of Contemporary Anthropology, TaiZhou Institute of Health Sciences and School of Life Sciences, Collaborative Innovation Center of Genetics and Development, Fudan University, Shanghai, China.
Ji QianState Key Lab of Genetic Engineering and MOE Key Lab of Contemporary Anthropology, TaiZhou Institute of Health Sciences and School of Life Sciences, Collaborative Innovation Center of Genetics and Development, Fudan University, Shanghai, China.
Guijuan LuoInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer, Shanghai, China.
Fangping HeState Key Lab Breeding Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Xinjiang 830054, China.
Xiaomei LuState Key Lab Breeding Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Xinjiang 830054, China.
Yibo DingDepartment of Epidemiology, Second Military Medical University, Shanghai 200433, China.
Yingchen YangInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China.
Wentao HuangInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China.
Guojun HouInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China.
Ximeng LinInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China.
Qin OuyangInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China.
Hengyu LiInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China.
Ruoyu WangEastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China.
Feng JiangJiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Hospital of Jiangsu Province, Nanjing, China.
Rui PuDepartment of Epidemiology, Second Military Medical University, Shanghai 200433, China.
Jianhua LuQidong Liver Cancer Institute and Nantong University Liver Cancer Institute, QiDong 226200, Jiangsu, China.
Mudan JinInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China.
Yexiong TanInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer, Shanghai, China.
Frank J GonzalezLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Guangwen CaoDepartment of Epidemiology, Second Military Medical University, Shanghai 200433, China.
Mengchao WuEastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China.
Hao WenState Key Lab Breeding Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Xinjiang 830054, China.
Tangchun WuMOE Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Rd, Wuhan 430030, China.
Li JinState Key Lab of Genetic Engineering and MOE Key Lab of Contemporary Anthropology, TaiZhou Institute of Health Sciences and School of Life Sciences, Collaborative Innovation Center of Genetics and Development, Fudan University, Shanghai, China.
Lei ChenInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer, Shanghai, China; Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: Chenlei@smmu.edu.cn.
Hongyang WangInternational Co-operation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China; National Center for Liver Cancer, Shanghai, China; National Laboratory for Oncogenes and Related Genes, Cancer Institute, RenJi Hospital, Shanghai Jiao Tong University, Shanghai 200441, China. Electronic address: hywangk@vip.sina.com.
Eastern Hepatobiliary Surgery Hospital · CNSecond Military Medical University · CNFirst Affiliated Hospital of Xinjiang Medical University · CNHuazhong University of Science and Technology · CNCenter for Cancer Research · USFudan University · CNJiangsu Cancer Hospital · CNQidong Liver Cancer Prevention Research · CNShanghai Cancer Institute · CNState Key Laboratory of Genetic EngineeringXinjiang Medical University · CN
Funding
Xenobiotic receptorsZIABC005562 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$26.9MXenobiotic ReceptorsZIABC005708 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GONZALEZ, FRANK J · 2009 to 2025
$16.4MIntramural NIH HHS ZIA BC005562Intramural NIH HHS ZIA BC005708
Abstract
The extremely poor prognosis of patients with symptomatic hepatocellular carcinoma (HCC) diagnosed clinically at advanced stages suggests an urgent need for biomarkers that can be used for prospective surveillance and pre-clinical screening for early presence of pre-malignant lesions and tumors. In a retrospective longitudinal phase 3 biomarker study in seven medical centers of China, time-series and 6 months interval-serum samples were collected from chronic hepatitis B virus infected (CHB) patient cohorts at the pre-malignant or pre-clinical stages (average 6 months prior to clinical diagnosis) and CHB patients that did not develop cancer, and circulating miRNAs measured. A set of serum miRNAs including miR-193a-3p, miR-369-5p, miR-672, miR-429 and let-7i* were identified in pre-clinical HCC patients and have the potential to screen for CHB patients at high risk to develop HCC 6-12 months after miRNAs measurement. These circulating miRNAs combined with the conventional screening tools using α-fetoprotein and ultrasound, may have great promise for the prediction and prevention of HCC in high-risk populations.
Indexed as
alpha-FetoproteinsBiomarkers, TumorCarcinoma, HepatocellularHepatitis B, ChronicHumansLiver NeoplasmsMicroRNAsROC Curvealpha-FetoproteinsBiomarkers, TumorMicroRNAsBiomarkerCirculating miRNAsHepatocellular carcinomaPredictionPrevention
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.